Phase 2Completed
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
A Single-Blind, Prospective Clinical Study to Assess the Efficacy, Safety and Tolerability of CGB-500 1% Tofacitinib Ointment vs. an Active Comparator for Atopic Dermatitis
- Sponsor
- CAGE Bio Inc. (Industry)
- Enrollment
- 3 enrolled
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- CGB-500 Ointment with 1% tofacitinib; Ruxolitinib 1.5% Cream QD
- Ages
- children, adults, older adults
- Registry
- NCT06923228
Full record on ClinicalTrials.gov
From the registry
The goal of this clinical trial is to learn if drug CGB-500 works to treat atopic dermatitis in subjects 12 years of age or older. It will also learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 decrease the severity of atopic dermatitis on the skin? What medical problems do participants have when taking drug CGB-500? Researchers will compare CGB-500 to a an approved product (1.5% ruxolitinib) to see if CGB-500 works to treat atopic dermatitis. Participants will: Apply CGB-500 and ruxolitinib to different locations on their body twice a day for four weeks. Visit the clinic six times for checkups and tests Keep a diary of their symptoms and when they apply the product
Primary outcomes
- evaluate effectiveness
- Safety and tolerability
History
Last registry update
Study completion
Primary completion
Started
Registered